Enhanced Granulosa Cell Responsiveness to Follicle-Stimulating Hormone during Insulin Infusion in Women with Polycystic Ovary Syndrome Treated with Pioglitazone

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 12, 2003, Pages 5624-5631

  Coffler, Mickey S ^a   Patel, Ketan ^a   Dahan, Michael H ^a   Yoo, Richard Y ^a   Malcom, Pamela J ^a   Chang, R Jeffrey ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; INSULIN; PIOGLITAZONE;

ADULT; ANOVULATION; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GRANULOSA CELL; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; GRANULOSA CELLS; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES;

FALLOPIA;

EID: 0347993157     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030745     Document Type: Article

References (43)

1. Yen SSC 1980 The polycystic ovary syndrome. Clin Endocrinol (Oxf) 12:177-207
2. Franks S 1989 Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 31:87-120
3. Erickson GF, Magoffin DA, Cragun JR, Chang RJ 1990 The effects of insulin and insulin-like growth factor-I and -II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab 70:894-902
4. Willis D, Mason H, Gilling-Smith C, Franks S 1996 Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 81:302-309
5. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632
6. Butzow TL, Lehtovirta M, Siegberg R, Hovatta O, Koistinen R, Seppala M, Apter D 2000 The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women. J Clin Endocrinol Metab 85:3271-3275
7. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K 1999 Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71:323-327
8. Huber-Buchholz MM, Carey DGP, Norman RJ 1999 Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84:1470-1474
9. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S 1992 Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 36:105-111
10. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146
11. Nestler JE, Jakubowicz D 1996 Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-622
12. Nestler JE, Jakubowicz DJ 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 82:4075-4079
13. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G 1999 Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314-1320
14. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L 1989 Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68:173-179
15. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-labate AM 2000 The effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767-2774
16. Pirwany IR, Yates RW, Cameron IT, Fleming R 1999 Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 14:2963-2968
17. Velazquez E, Acosta A, Mendoza SG 1997 Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90:392-395
18. Velazquez EM, Mendoza S, Hamer T, Sosa F, CJG 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654
19. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876-1880
20. Holte J, Bergh T, Berne C, Wide L, Lithell H 1995 Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:2586-2593
21. Coffler MS, Patel KS, Dahan MH, Malcom PJ, Kawashima T, Deutsch R, Chang RJ 2003 Evidence for abnormal granulosa cell responsiveness to follicle stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:1742-1747
22. Adams J, Polson DW, Franks S 1986 Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. 293:355-359
23. Bergman RN, Phillips LS, Cobelli C 1981 Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467
24. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F 1976 Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. 57:1320-1329
25. DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, Chang RJ 1985 Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease. Fertil Steril 44:453-459
26. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D, Franks S 1996 Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 81:3821-3824
27. Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J 1998 Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. 83:423-426
28. El-Roeiy A, Chen X, Roberts VJ, LeRoith D, Roberts Jr CT, Yen SSC 1993 Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab 77:1411-1418
29. El-Roeiy A, Chen X, Roberts VJ, Shimasakai S, Ling N, LeRoith D, Roberts Jr CT, Yen SS 1994 Expression of the genes encoding the insulin-like growth factors IGF-I and II, the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 78:1488-1496
30. Ciaraldi TP, Coffler MS, Erickson GF, Soules MR, Henry RR, Chang RJ 2001 Intracellular insulin and IGF-I signaling in the polycystic ovary. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 377 (Abstract P2-395)
31. Das S, Maizels ET, DeManno D, St Clair E, Adam SA, Hunzicker-Dunn M 1996 A stimulatory role of cyclic adenosine 3′,5′-monophosphate in follicle-stimulating hormone-activated mitogen-activated protein kinase signaling pathway in rat ovarian granulosa cells. Endocrinology 137:967-974
32. Cameron MR, Foster JS, Bukovsky A, Wimalasena J 1996 Activation of mitogen-activated protein kinases by gonadotropins and cyclic adenosine 5′-monophosphates in porcine granulosa cells. Biol Reprod 55:111-119
33. Babu PS, Krishnamurthy H, Chedrese PJ, Sairam MR 2000 Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor. J Biol Chem 275:27615-27626
34. Imamura T, Huang J, Dalle S, Ugi S, Usui I, Luttrell LM, Miller WE, Lefkowitz RJ, Olefsky JM 2001 β-Arrestin-mediated recruitment of the Src family kinase yes mediates endothelin-1-stimulated glucose transport. J Biol Chem 276:43663-43667
35. Dalle S, Imamura T, Rose DW, Worrall DS, Ugi S, Hupfeld CJ, Olefsky JM 2002 Insulin induces heterologous desensitization of G protein-coupled receptor and insulin-like growth factor 1 signaling by downregulating β-attestin-1. Mol Cell Biol 22:6272-6285
36. Hupfeld CJ, Dalle S, Olefsky JM 2003 β-Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of β2 adrenergic receptor Gαs signaling in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 100:161-166
37. Almahbobi G, Anderiesz C, Hutchinson P, McFarlane JR, Wood C, Trounson AO 1996 Functional integrity of granulosa cells from polycystic ovaries. Clin Endocrinol 44:571-580
38. Gasic S, Bodenburg Y, Nagamani M, Green A, Urban RJ 1998 Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 139:4962-4966
39. Gasic S, Nagamani M, Green A, Urban RJ 2001 Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynecol 184:575-579
40. Arlt W, Auchus RJ, Miller WL 2001 Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 276:16767-16771
41. Mu Y-M, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H 2000 Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 271:710-713
42. Dunaif A, Graf M 1989 Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest 83:23-29
43. Patel KS, Coffler MS, Dahan MH, Yoo RY, Malcom PJ, Chang RJ 2003 Suppression of increased pituitary LH secretion in polycystic ovary syndrome (PCOS) by hyperinsulinemia. Proc Soc Gyn Invest (Abstract 250990)